China approves Pfizer Covid pill

China approves Pfizer Covid pill

Emergency authorisation the first by Beijing for a foreign coronavirus treatment

A box of Paxlovid pills for treating Covid-19 is seen at Misericordia hospital in Grosseto, Italy. (Reuters Photo)
A box of Paxlovid pills for treating Covid-19 is seen at Misericordia hospital in Grosseto, Italy. (Reuters Photo)

China has granted emergency approval for a Pfizer Covid-19 pill in a promising sign that the country could open up further to foreign vaccines and treatments for the virus.

The import registration for Paxlovid was approved on Friday, the National Medical Products Administration said in a statement on its website on Saturday. The Chinese regulator requires relevant research work to continue to be carried out, with conditional requirements completed within a time limit, and the follow-up research results submitted in a timely manner, according to the statement.

The emergency approval is the first that China has given to a drug or vaccine developed by a foreign country for Covid-19. The mRNA Covid vaccine co-developed by Pfizer and BioNTech, for which Shanghai Fosun Pharmaceutical Group holds the rights to distribute in Greater China, has not yet been approved in the country. 

China’s homegrown efforts to develop Covid antivirals have largely lagged those of the West, with the most advanced still in the final stage of trials at sites outside of the country. Such treatments could be critical to help China move away from its zero-Covid approach to managing the virus.  

After containing the virus with mass testing, surveillance and rigid border curbs, China is now uniquely vulnerable to the pathogen as it has little natural protection from prior infections. The country’s vaccination campaign has also relied on homegrown inactivated inoculations that have been less effective at blocking infections than the highly potent mRNA shots that are widely used elsewhere. 

In December, China approved a homegrown antibody therapy that needs to be administered through intravenous injections at hospitals. The two treatments co-developed by Brii Biosciences were approved for use on adults and teenage patients in mild to moderate cases.


Do you like the content of this article?
COMMENT (4)

New Ukraine push

Putin is preparing a new offensive in Ukraine, at the same time steeling his country for a conflict with the US and its allies that he expects to last for years.

12:42

Myanmar junta plans poll with strict rules for political parties

Myanmar’s military government took an early step toward holding parliamentary elections, but it did so by imposing strict rules on political parties that may make fair balloting difficult.

11:14

Finance Ministry maintains growth outlook, expects more tourists

The Ministry of Finance has maintained its economic growth outlook for 2023 at 3.8%, buoyed by a rebound in tourism and domestic demand, but an official said exports would slow down this year.

10:48